- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03148847
Management of Cardiogenic Pulmonary Edema (RENAU-OAP) (RENAU-OAP)
Evaluation of Professional Practices on the Management of Cardiogenic Pulmonary Edema (RENAU-OAP)
The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to french disability-health surveys. In France, more than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in many cancers. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.
The severity of cardiogenic pulmonary edema depends on several factors such as etiology, hemodynamic status, effect on hematosis, and fatigue.
It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.
The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating guidelines on cardiogenic pulmonary edema management which will then be assessed.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The prevalence of heart failure is estimated to 2.3 percent of the adult population and strongly increases with age, according to disability-health surveys in France. In recent years, effective treatments (revascularization in percutaneous coronary intervention, circulatory assistance) helped reduce mortality in post-myocardial infarction, which combined with the increase of life expectancy has led to an increase number of patients with chronic heart failure. More than 32,000 annual deaths are attributable to heart failure and the five-year survival rate is similar to those found in cancers of the breast, bladder, colon, ovarian, and prostate. A better therapeutic management (angiotensin converting enzyme inhibitor and beta-blockers) helped reduce mortality after an episode of heart failure requiring hospitalization, but, nevertheless it remains high.
Main clinical manifestations are those of left heart failure, such as cardiogenic pulmonary edema which is a medical emergency. Treatment must take into account pathophysiological aspects of heart failure, etiologies of cardiogenic pulmonary edema and any potential factors or triggers apart from general measures. Two consensus statements and an international recommendation help define therapeutic strategies in this particular situation.
Signs suggestive of cardiogenic pulmonary edema include orthopnea, bilateral crackles or wheezing (patients over 70 years without known asthma), edema of the lower limbs, and gallop sound on heart auscultation. The evolution of these signs makes it particularly possible to manage the response to the treatment. The severity of cardiogenic pulmonary edema depends on several factors such as etiology (ECG analysis and chest pain assessment for acute coronary syndrome), hemodynamic status (blood pressure, heart rate), effect on hematosis (cyanosis, oxygen saturation), and fatigue (low respiratory rate with persistent cardiogenic pulmonary edema signs). The respiratory rate represents a simple clinical feature that can be used to quantify dyspnea (sign of severity if greater than 30 per minute in adults) and then follow its evolution (improvement, exhaustion). Disorders of consciousness can testify to the severity of the hemodynamic state and/or exhaustion.
Cardiogenic pulmonary edema management without shock implies urgent administration of vasodilators (trinitrin) and intravenous loop diuretics in presence of congestion signs along with the establishment of a system of care adapted to severity (Emergency Mobile Services or ambulance, hospitalization in Intensive Care Unit, intensive cardiology unit, cardiology or medicine department, or emergency passage). The subsequent therapeutic management will especially depend on initial treatment by the primary care physician, so it is preferable to record doses and hours of medications. Non-hospitalization must remain exceptional for non-severe decompensation with rapidly favorable evolution.
The French Observatory of Acute Heart Failure (OFICA) including nearly 1,800 patients specified epidemiological and therapeutic data of patients hospitalized for cardiogenic pulmonary edema in 2009. However, this study did not describe the initial management of the Mobile Emergency and Resuscitation Service and emergency services of hospitals. It is important to note that cardiogenic pulmonary edema initial management is decisive. In addition, early and adapted management of cardiogenic pulmonary edema is associated with a shorter hospital stay and reduced hospital mortality.
The Coronary Emergency Network (RESURCOR) within the Northern French Alps Emergency Network (RENAU) is an emergency care system structured in the departments of Isère, Savoie and Haute-Savoie. Its main goal is to help improve emergency management by using regional good practice guidelines (www.renau.org). In this context, projects aiming to evaluate professional practices are developed regularly. Since emergency management of cardiogenic pulmonary edema has not been evaluated, the Northern French Alps Emergency Network offers an approach to improve professional practices by defining and disseminating a guideline on cardiogenic pulmonary edema management which will then be assessed.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Pringy, France, F-74374
- Ch Annecy Genevois
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
As the goal of this study is to analyze common practices, data from the french medicalized information system program will be used to select a study population as exhaustive as possible.
This program is dedicated to systematic collection of data from hospital stays. Each hospital stay is identified by a unique number and a diagnosis is attributed for each, at the end of every hospital stay. Diagnosis are based on the International Classification of Diseases (ICD-10). At hospital levels, a unique stay number can be related to names and addresses of involved patients.
French medicalized information system program data are analyzed at a regional and then a national level.
For this study, cases will be screened if they had a I500, I501 and I509 ICD-10 diagnosis (main or associated).
Description
Inclusion Criteria:
- ≥18 years old
- hospitalization during one of the two designed period (either year 2013, or year 2017) in a center belonging to Northern French Alps Emergency Network
- diagnosis of cardiogenic pulmonary edema, or heart failure (either left-sided, congestive or unspecified)
Exclusion Criteria:
- people who refuse to have their health information used will not be included
- people whose care will have begun in a center not belonging to the Northern French Alps Emergency Network
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Baseline care
Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2013 and December 31, 2013
|
|
Referential's dissemination
Patients treated for Cardiogenic Pulmonary Edema into the Northern French Alps Emergency Network between January 1, 2017 and December 31, 2017, after referential's dissemination for management of patients with paroxysmal dyspnea due to left sided heart failure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of quality of initial care of patients with cardiogenic pulmonary edema after dissemination of good practice standards
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Two kinds of predefined quality indicators will be evaluated at different stages of care and compared among the two periods, before and after dissemination of good practice standards, looking for informations in medical charts during the management of patients either care by Mobile Emergency and Resuscitation Services or at emergency departments and in mails at time of hospital discharge).
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' description at the onset of cardiogenic pulmonary edema (clinical)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Clinical characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Patients' description at the onset of cardiogenic pulmonary edema (biological)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Biological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Patients' description at the onset of cardiogenic pulmonary edema (radiological)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Radiological characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Patients' description at the onset of cardiogenic pulmonary edema (echocardiographic)
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Echocardiographic characteristics of patients with cardiogenic pulmonary edema included in the two parts of this observational study (whole population).
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Mortality of patients hospitalized for cardiogenic pulmonary edema
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
number of patients dying during hospitalization for cardiogenic pulmonary edema
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Needs for Hospitalization in intensive care units
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
number (and rate) of patients with cardiogenic pulmonary edema, requiring hospitalization in intensive care unit
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Needs for respiratory assistance
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
number of patients and kind of respiratory assistance for patients with cardiogenic pulmonary edema
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Inter-services transfers
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
number of patients who require transfers from an emergency room (or a cardiology ward) to intensive care units and vice-versa
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Length of stay in hospital
Time Frame: an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
number of days between arrival and discharge
|
an average of 1 week (length of hospitalization for cardiogenic pulmonary edema)
|
Re-hospitalizations during the first six months
Time Frame: up to six months
|
number of re-hospitalizations during the first six months after the onset of cardiogenic pulmonary edema
|
up to six months
|
Collaborators and Investigators
Investigators
- Study Chair: Loic BELLE, MD, Centre Hospitalier Annecy Genevois
Publications and helpful links
General Publications
- McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Kober L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Ronnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012 Jul;33(14):1787-847. doi: 10.1093/eurheartj/ehs104. Epub 2012 May 19. No abstract available. Erratum In: Eur Heart J. 2013 Jan;34(2):158.
- Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001 Nov 8;345(19):1368-77. doi: 10.1056/NEJMoa010307.
- Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJ. More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001 Jun;3(3):315-22. doi: 10.1016/s1388-9842(00)00141-0.
- Mebazaa A, Gheorghiade M, Pina IL, Harjola VP, Hollenberg SM, Follath F, Rhodes A, Plaisance P, Roland E, Nieminen M, Komajda M, Parkhomenko A, Masip J, Zannad F, Filippatos G. Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med. 2008 Jan;36(1 Suppl):S129-39. doi: 10.1097/01.CCM.0000296274.51933.4C.
- Heart Failure Society Of America. HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006 Feb;12(1):e1-2. doi: 10.1016/j.cardfail.2005.11.005.
- Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med. 2003;4 Suppl 7:S13-20.
- Peacock WF 4th, Emerman CL. Emergency department management of patients with acute decompensated heart failure. Heart Fail Rev. 2004 Jul;9(3):187-93. doi: 10.1007/s10741-005-6128-5.
- Belle L, Fourny M, Reynaud T, Hammer L, Vanzetto G, Labarere J; RENAU-RESURCOR study investigators. Efficacy and safety of glycoprotein IIb/IIIa receptor antagonists for patients undergoing percutaneous coronary intervention within twelve hours of fibrinolysis. Catheter Cardiovasc Interv. 2011 Sep 1;78(3):376-84. doi: 10.1002/ccd.22825. Epub 2011 Mar 16.
- Chacornac M, Baronne-Rochette G, Schmidt MH, Savary D, Habold D, Bouvaist H, Marliere S, Belle L, Machecourt J, Vanzetto G; REseau des URgences CORonariennes (RESURCOR). Characteristics and management of acute ST-segment elevation myocardial infarctions occurring in ski resorts in the French Alps: Impact of an acute coronary care network. Arch Cardiovasc Dis. 2010 Aug-Sep;103(8-9):460-8. doi: 10.1016/j.acvd.2010.09.002. Epub 2010 Oct 30.
- Debaty G, Belle L, Labarere J, Fourny M, Torres JP, Savary D, Usseglio P, Menthonnex E, Guenot O, Vanzetto G. [Evolution of strategies of revascularisation in acute coronary syndromes with ST elevation. Analysis of the data of RESURCOR]. Arch Mal Coeur Vaiss. 2007 Feb;100(2):105-11. French.
- Ferrier C, Belle L, Labarere J, Fourny M, Vanzetto G, Guenot O, Debaty G, Savary D, Machecourt J, Francois P. [Comparison of mortality according to the revascularisation strategies and the symptom-to-management delay in ST-segment elevation myocardial infarction]. Arch Mal Coeur Vaiss. 2007 Jan;100(1):13-9. French.
- Fourny M, Belle L, Labarere J, Senee D, Savary D, Debaty G, Vanzetto G, Francois P. [Analysis of the accuracy of a coronary syndrome register]. Arch Mal Coeur Vaiss. 2006 Sep;99(9):798-803. French.
- Fourny M, Lucas AS, Belle L, Debaty G, Casez P, Bouvaist H, Francois P, Vanzetto G, Labarere J. Inappropriate dispatcher decision for emergency medical service users with acute myocardial infarction. Am J Emerg Med. 2011 Jan;29(1):37-42. doi: 10.1016/j.ajem.2009.07.008. Epub 2010 Mar 9.
- Zannad F, Briancon S, Juilliere Y, Mertes PM, Villemot JP, Alla F, Virion JM. Incidence, clinical and etiologic features, and outcomes of advanced chronic heart failure: the EPICAL Study. Epidemiologie de l'Insuffisance Cardiaque Avancee en Lorraine. J Am Coll Cardiol. 1999 Mar;33(3):734-42. doi: 10.1016/s0735-1097(98)00634-2. Erratum In: J Am Coll Cardiol 1999 Oct;34(4):1363.
- Delahaye F, Roth O, Aupetit JF, de Gevigney G. [Epidemiology and prognosis of cardiac insufficiency]. Arch Mal Coeur Vaiss. 2001 Dec;94(12):1393-403. French.
- Schaufelberger M, Swedberg K, Koster M, Rosen M, Rosengren A. Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. Eur Heart J. 2004 Feb;25(4):300-7. doi: 10.1016/j.ehj.2003.12.012.
- Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, Galinier M, Mulak G, Donal E, Delahaye F, Juilliere Y, Damy T, Jourdain P, Bauer F, Eicher JC, Neuder Y, Trochu JN; Heart Failure of the French Society of Cardiology. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013 Apr;15(4):465-76. doi: 10.1093/eurjhf/hfs189. Epub 2012 Nov 27.
- Logeart D. [The OFICA study of acute heart failure]. Soins. 2013 Apr;(774):35. No abstract available. French.
- Nguyen HB, Rivers EP, Havstad S, Knoblich B, Ressler JA, Muzzin AM, Tomlanovich MC. Critical care in the emergency department: A physiologic assessment and outcome evaluation. Acad Emerg Med. 2000 Dec;7(12):1354-61. doi: 10.1111/j.1553-2712.2000.tb00492.x.
- Sebat F, Johnson D, Musthafa AA, Watnik M, Moore S, Henry K, Saari M. A multidisciplinary community hospital program for early and rapid resuscitation of shock in nontrauma patients. Chest. 2005 May;127(5):1729-43. doi: 10.1378/chest.127.5.1729.
- Masip J, Roque M, Sanchez B, Fernandez R, Subirana M, Exposito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005 Dec 28;294(24):3124-30. doi: 10.1001/jama.294.24.3124.
- Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD. Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis. Lancet. 2006 Apr 8;367(9517):1155-63. doi: 10.1016/S0140-6736(06)68506-1.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-RENAU-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dyspnea, Paroxysmal
-
University of CologneTeva Branded Pharmaceutical Products R&D, Inc.CompletedCancer | Dyspnea, ParoxysmalGermany
-
Assistance Publique - Hôpitaux de ParisCompletedCongestive Heart Failure | Pulmonary Edema | Dyspnea | ParoxysmalFrance
-
Erasmus Medical CenterUnknownTachycardia, Supraventricular | Tachycardia; Paroxysmal, SupraventricularNetherlands
-
Apellis Pharmaceuticals, Inc.RecruitingParoxysmal Nocturnal Hemoglobinuria (PNH) | Paroxysmal HemoglobinuriaMalaysia, United States, Czechia, France, Netherlands, Serbia, Spain, Thailand, United Kingdom
-
Assistance Publique - Hôpitaux de ParisRecruitingDyspnea Invasive Mechanical Ventilation-associatedFrance
-
Novartis PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria PNHLithuania, Japan, Czechia
-
Ra PharmaceuticalsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United States
-
Alexion PharmaceuticalsAchillion, a wholly owned subsidiary of AlexionCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)United Kingdom, New Zealand, Korea, Republic of, Italy
-
AKARI TherapeuticsCompletedParoxysmal Nocturnal Hemoglobinuria (PNH)Kazakhstan, Lithuania, Sri Lanka
-
Alexion PharmaceuticalsTerminatedParoxysmal Nocturnal Hemoglobinuria (PNH)United States, Czech Republic, Italy, Poland, United Kingdom
Clinical Trials on Baseline care
-
Medical College of WisconsinNational Institute of Mental Health (NIMH)CompletedHIV Prevention and Assessment ReactivitySouth Africa
-
National Institute of Allergy and Infectious Diseases...Boston Children's Hospital; Benaroya Research InstituteCompletedSARS-CoV-2 | Coronavirus Disease 2019 (COVID-19)United States
-
Queen's University, BelfastWellcome TrustCompletedMild Cognitive ImpairmentUnited Kingdom
-
Memorial Sloan Kettering Cancer CenterCompletedPostoperative CareUnited States
-
Procare Health Iberia S.L.CompletedFemale Sexual DysfunctionSpain
-
University GhentCompletedDiabetes MellitusBelgium
-
University of AlbertaAlberta Health services; Alberta Innovates Health Solutions; Covenant HealthRecruitingNeonatal Abstinence SyndromeCanada
-
Baxter Healthcare CorporationCompletedOsteoarthritis | Knee Replacement SurgeryUnited States
-
University Hospital Inselspital, BerneCompletedBreast CancerSwitzerland
-
Hopital FochCompleted